Usefulness of soluble tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors R2 and R3 in progression assessment of gastroenteropancreatic neuroendocrine neoplasms – A preliminary study

#4654

Introduction: TRAIL is a member of TNF family and appears in membrane and soluble (s) forms. It acts either triggering (R1 and R2) or blocking (R3 and R4) apoptosis. TRAIL targeted therapy is widely studied and known as potentially effective in number of neoplasms.

Aim(s): Evaluation of plasma levels of sTRAIL, sTRAIL-R2 and sTRAIL-R3 in patients with well-differentiated GEP-NEN in stage IV.

Materials and methods: We studied prospectively 12 patients with well-differentiated GEP-NEN (Ki-67 <10%, WHO 2019) with metastasis in the liver and treated with long-acting somatostatin analogues (SSA) or SSA combined with polypeptide receptor radionuclide therapy (SSA+PRRT). Plasma samples were collected at the time of enrolment in the study and after 6 months, along with radiological assessment of the disease. Markers’ levels were measured in healthy controls (HC; N=19) as well. To determine soluble markers’ plasma levels, we used multi-analyte kit, Luminex Screening Assay.

Conference:

Presenting Author: Kaczmarska-Turek D

Authors: Kaczmarska-Turek D, Radziszewski M, Matałowski M, Liszcz A, Bartoszewicz Z,

Keywords: gastroenteropancreatic neuroendocrine neoplasm, tumour necrosis factor-related apoptosis-inducing ligand, tumour progression, PRRT, TRAIL, GEP-NEN,